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Translational Relevance 
Tumor-infiltrating lymphocytes (TILs) in pre-treatment biopsies are associated with lower 
mortality in triple-negative breast cancer (TNBC). We investigated whether higher peripheral 
lymphocyte counts are associated with lower breast cancer-specific mortality (BCM) and overall 
mortatlity (OM) in TNBC. On multivariable analysis, we found that higher minimum absolute 
lymphocyte count, but not absolute neutrophil count, predicted improved OM and BCM. Five-
year probability of BCM was 15% for patients who were ever lymphopenic versus 4% for those 
who were not. An exploratory analysis (N=70) showed a significant association between TILs 
and higher peripheral lymphocyte counts during neoadjuvant chemotherapy. The results 
contribute to an emerging understanding of immune function in TNBC. In future clinical trials 
for TNBC, peripheral lymphocyte counts should be explored in connection with TILs as a 
potential biomarker for treatment efficacy and cancer mortality. 
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Abstract 
Background: Tumor-infiltrating lymphocytes (TILs) in pre-treatment biopsies are associated 
with improved survival in triple-negative breast cancer (TNBC). We investigated whether higher 
peripheral lymphocyte counts are associated with lower breast cancer-specific mortality (BCM) 
and overall mortality (OM) in TNBC. 
 
Methods: Data on treatments and diagnostic tests from electronic medical records of two 
healthcare systems were linked with demographic, clinical, pathologic, and mortality data from 
the California Cancer Registry. Multivariable regression models adjusted for age, race/ethnicity, 
socioeconomic status, cancer stage, grade, neoadjuvant/adjuvant chemotherapy use, radiotherapy 
use, and germline BRCA1/2 mutations were used to evaluate associations between absolute 
lymphocyte count (ALC), BCM and OM. For a subgroup with TILs data available, we explored 
the relationship between TILs and peripheral lymphocyte counts. 
 
Results: 1,463 Stage I-III TNBC patients were diagnosed from 2000-2014; 1113 (76%) received 
neoadjuvant/adjuvant chemotherapy within one year of diagnosis. Of 759 patients with available 
ALC data, 481 (63.4%) were ever lymphopenic (minimum ALC <1.0 K/μL). On multivariable 
analysis, higher minimum ALC, but not absolute neutrophil count, predicted lower OM (hazard 
ratio [HR]: 0.23, 95% confidence interval [CI]: 0.16-0.35) and BCM (HR: 0.19, CI: 0.11-0.34). 
Five-year probability of BCM was 15% for patients who were ever lymphopenic versus 4% for 
those who were not. An exploratory analysis (N=70) showed a significant association between 
TILs and higher peripheral lymphocyte counts during neoadjuvant chemotherapy. 
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Conclusion: Higher peripheral lymphocyte counts predicted lower mortality from early-stage, 
potentially curable TNBC, suggesting that immune function may enhance the effectiveness of 
early TNBC treatment.  
 
 
 
 
 
 
 
  
Research. 
on March 28, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 26, 2018; DOI: 10.1158/1078-0432.CCR-17-1323 
 7 
Introduction 
Many factors influence breast cancer patients’ risk of death, including age and comorbid 
conditions, tumor subtype, grade and stage, and treatments received. Prior studies have shown 
that lymphopenia, or a low peripheral blood lymphocyte count, may also be a harbinger of worse 
mortality from advanced carcinomas, sarcomas and lymphomas (1-7). An association between 
lymphopenia and poor mortality outcomes in breast cancer was reported in 1976 (4) and later 
confirmed in two studies showing an associated risk of recurrence after primary surgery and 
neoadjuvant therapy (5, 7). Several recent studies have demonstrated lower breast cancer-
specific mortality associated with tumor-infiltrating lymphocytes (TILs) in patients treated with 
neoadjuvant/adjuvant chemotherapy. This is particularly notable with triple-negative breast 
cancer (TNBC) (8-12), the breast cancer subtype that is defined by a lack of estrogen and 
progesterone receptor expression and of HER2 receptor over-amplification and has relatively 
high mortality (13). 
 
Emerging immune checkpoint inhibitors, particularly antibodies against programmed death 
receptor 1 (PD-1) and its ligand (PD-L1) (14-17), have shown promising results across cancer 
types, including in early-phase clinical trials among TNBC patients (16-19). Given this evolving 
therapeutic area, we investigated whether peripheral lymphocyte levels as measured by absolute 
lymphocyte count (ALC) have a similar prognostic effect as TILs in TNBC (8-12). We took 
advantage of the Oncoshare database, which integrates electronic medical records (EMRs) of 
two Northern California healthcare systems with records of the California Cancer Registry 
(CCR, a contributing registry of the Surveillance, Epidemiology and End Results [SEER] 
program (20)), to evaluate the following three aims; 1) factors associated with lymphopenia, 2) 
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the association between ALC and mortality, and 3) the variation in strength of association 
between ALC and mortality over time among patients diagnosed with early-stage TNBC from 
2000-2014. As a secondary exploratory analysis, we evaluated the relationship between 
peripheral blood lymphocytes and TILs among 70 patients with pre-treatment TIL information.  
 
Methods 
Oncoshare Data Resource  
Data were collected using Oncoshare, a breast cancer outcomes research database that integrates 
EMR data from breast cancer patients treated at Stanford University Hospital and/or the 
community-based Palo Alto Medical Foundation (20, 21). Oncoshare links patient-level clinical 
data from EMRs to population-based CCR (SEER) data (22-24). The CCR, with mandated 
statewide reporting, provides a gold standard for patient identification, cancer staging and long-
term follow-up. Methods involved in developing Oncoshare, including validation of the data 
linkage approach, have been published (20, 21). In brief, clinical data from the two healthcare 
systems were extracted from EMRs, and drug data elements and laboratory results from EMRs 
were mapped to a standardized lexicon (25). CCR records were requested for all patients with 
breast cancer treated at either of the two healthcare systems. Data from EMRs and CCR were 
then linked on an individual patient level and de-identified before research use. All research was 
approved by the Institutional Review Boards of Stanford University, Palo Alto Medical 
Foundation Research Institute, and the State of California. 
 
Variable Definitions and Sources 
Variables from the CCR included age and race/ethnicity; cancer stage, grade, 
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estrogen/progesterone receptor (ER/PR), and HER2 status; and summary of initial treatment 
course, including surgery, neoadjuvant/adjuvant chemotherapy, and radiation therapy, 
administered by any treating institution in California. TNBC was defined as breast cancer that 
had no ER/PR staining using immunohistochemistry and no overexpression or amplification of 
HER2. Breast cancer-specific mortality (BCM) and overall mortality (OM) data were derived 
from the CCR, which collects this information using routine linkages with the Social Security 
Death Master File, the Registry of Motor Vehicles, and other national databases (26). OM was 
defined as the time from breast cancer diagnosis to death for any reason or the day of last follow-
up. BCM was defined as the time from breast cancer diagnosis to breast cancer-specific death or 
the day of last follow-up. Neighborhood socioeconomic status (nSES, at the Census block-group 
level and in terms of statewide quintiles) was assigned based on Census data using the validated 
Yost index (27).  
 
EMR data included receipt of neoadjuvant/adjuvant chemotherapy and radiation therapy and 
laboratory values. Ever lymphopenic was defined as having an ALC <1 K/µL, and ever 
neutropenic as having an absolute neutrophil count (ANC) <1 K/µL, anytime after TNBC 
diagnosis. Minimum ALC was defined as the lowest value of all reported ALC measures 
anytime after TNBC diagnosis. If a patient had only one ALC value measured, then it was set as 
the minimum. Minimum percent lymphocyte count was included as an additional measure of 
lymphopenia.  
 
Germline BRCA1 and BRCA2 (BRCA1/2) mutation status (tested and positive for a deleterious 
mutation; tested and negative for a deleterious mutation; tested and had a variant of uncertain 
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significance [VUS]; not tested or unknown) was obtained from Myriad Genetics, Inc. (Salt Lake 
City, UT), which was the single source of clinical BRCA1/2 testing during the study time-frame 
(28).  
 
Inclusion and Exclusion Criteria 
All patients in the Oncoshare database diagnosed with stages I-III TNBC between January 2000 
and May 2014 were eligible. To restrict consideration of neoadjuvant/adjuvant chemotherapy to 
treatment which was undertaken for curative intent rather than for metastatic cancer, the 
chemotherapy receipt variable was limited to within one year of the initial breast cancer 
diagnosis. Patients were followed through May 31, 2014.    
 
Exploratory Analysis of TILs and Peripheral Blood Lymphocytes 
In an exploratory analysis of 70 patients who participated in a Phase II clinical trial of 
neoadjuvant carboplatin, gemcitabine and iniparib (PrECOG 0105) (12, 29), we evaluated the 
association between pre-treatment stromal TILs and peripheral blood lymphocytes. Stromal TIL 
values were reported in deciles (0=0%, 1=10%, 2=20%, etc. of tumor stroma containing 
lymphocytes not in direct contact with tumor cells) as per consensus guidelines (30). Pre-
treatment and minimum lymphocyte values during treatment and up to 30 days post-treatment 
were reported as percentages and absolute counts.   
 
Statistical Analysis 
A logistic regression model was fit to whether or not a patient was ever lymphopenic as a 
function of cancer stage, grade, neoadjuvant/adjuvant chemotherapy use, radiotherapy use, 
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nSES, race/ethnicity, BRCA1/2 mutation status (positive for a deleterious mutation; negative for 
a deleterious mutation and/or having a VUS, the latter two of which were combined as a single 
category given their similar clinical management; untested or unknown), age at diagnosis, and 
ever neutropenic. Odds ratios (OR) and 95% confidence intervals (CIs) were estimated. 
 
Multivariable Cox regression models were fit to examine the association between minimum ALC 
and OM, and minimum ALC and BCM, adjusting for all covariates described above. Data from 
patients who were alive through the last follow-up date were censored. Hazard ratios (HR) and 
95% CIs were computed. To determine five-year survival and the 95% confidence limits among 
ever- and never-lymphopenic patients, the survest function from the rms package in R was 
implemented using estimates from our fitted models and the mean and mode values for each of 
the continuous or categorical predictors, respectively (31). For models that adjusted for 
additional covariates, primary analyses used a complete case approach, excluding patients with 
missing data. Given the high rate of patients without germline BRCA1/2 testing or reported ALC 
values, multiple imputation methods were implemented using the default settings of the MICE 
package in R (32), with five imputations used (33, 34). As a sensitivity analysis on using 
minimum ALC to measure lymphopenia, multivariable Cox regression models were fit, 
replacing minimum ALC with minimum percent lymphocyte count and adjusting for the 
covariates described above. 
 
We used mixed effects logistic regression techniques to evaluate the association between 
mortality outcomes and time-varying ALC. All ALC values within each time interval were 
included. The two outcomes were indicators for whether or not OM or BCM occurred. The 
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models included time since diagnosis, time-varying ALC value, and their interaction 
(representing how the magnitude of association between ALC and mortality varied over time). A 
subject-specific random effect was included to account for correlation of observations within a 
given patient over time. In order to report the effect of ALC on mortality by years since 
diagnosis, we calculated contrasts from the interaction term for year 1 through year 6. Due to 
convergence issues, no other covariates were included in these models. OM and BCM for ever-
lymphopenic and never-lymphopenic patients were displayed using Kaplan-Meier curves. For 
the exploratory analysis of baseline TILs and peripheral lymphocyte counts, we used the 
Spearman rank correlation test and reported the associated p-value and Spearman’s rho. We 
performed all statistical analyses in R (Version 3.2.2, Vienna, Austria). All tests were two-sided 
and statistical significance used an alpha threshold of 0.05.  
 
Results 
Patient Characteristics 
From January 1, 2000 through May 31, 2014, 1,463 patients were diagnosed with stages I-III 
TNBC and treated at Stanford University Hospital and/or Palo Alto Medical Foundation 
(Supplemental Figure 1). Mean age at diagnosis was 54 years and most were non-Hispanic 
(NH) white (72%), followed by NH Asian/Pacific Islander (14%). Most were of the second-
highest nSES quintile. Nearly half (49%) had Stage II and three-quarters had high-grade disease 
(73%). Three-quarters received either adjuvant or neoadjuvant chemotherapy (76%) and 
approximately half (46%) received adjuvant radiotherapy. Nearly one-quarter (23%) were tested 
clinically for BRCA1/2 mutations, of whom 80 (24% of tested patients) carried a deleterious 
mutation in either or both genes. Most (81%) were never neutropenic (ANC <1.0 K/µL), yet 
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most (63.4%) were lymphopenic (ALC  <1.0 K/µL) with a mean minimum ALC value of 0.9 
K/µL (Table 1).   
 
Over a median follow-up time of 4.5 years, 352 (24%) patients died, with 222 (63%) of these 
deaths from breast cancer. Approximately half (759, 52%) had at least one ALC value reported. 
In comparison to the full cohort, those with ALC values were slightly more likely to receive 
neoadjuvant/adjuvant chemotherapy (81% versus 76%) and BRCA1/2 testing (29% versus 23%, 
Table 1).  
 
Factors Associated with Lymphopenia 
On our primary multivariable analysis, which only included variables that did not vary with time, 
higher stage was positively associated with lymphopenia  (OR: 1.84, 95% CI: 1.03-3.28) (Table 
2). Exploratory analysis including variables with temporal sequences showed that 
neoadjuvant/adjuvant chemotherapy use (OR: 2.66, 95% CI: 1.72-4.15), higher nSES (OR: 1.18, 
95% CI: 1.03-1.36), ever being neutropenic (OR: 6.05, 95% CI: 3.46-11.35), and higher stage 
(OR: 1.73, 95% CI: 1.02-3.01) were positively associated with lymphopenia (Supplemental 
Table 1).   
 
Minimum ALC, OM and BCM 
The number of reported ALC values ranged from 1-117 (mean 14, median 10). No significant 
difference in OM or BCM was observed between patients who had <10 (the median), versus ≥10 
measured ALC values, and only minimal increases in OM (HR: 1.02, 95% CI: 1.01-1.03) and 
BCM (HR: 1.02, 95% CI: 1.01-10,2) were associated with the number of measured ALC values 
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when that number was analyzed as a continuous variable. On multivariable analysis, patients 
with higher minimum ALC had significantly lower overall mortality than those with lower 
minimum ALC (HR: 0.23, 95% CI: 0.16-0.35). Other predictors of lower OM were receiving 
neoadjuvant/adjuvant chemotherapy (HR: 0.53, 95% CI: 0.34-0.84) and higher nSES (HR 0.85, 
CI: 0.74-0.97). Higher stage was associated with higher OM (III versus I HR: 4.25, CI: 2.69-
6.74) (Table 3, Figure 1).  
 
Higher minimum ALC was also significantly associated with lower BCM (HR: 0.19; CI: 0.11-
0.34), as was higher nSES (HR 0.85; CI: 0.71-1.00). Higher stage (Stage III versus Stage I HR: 
7.59; CI: 3.83-15.0) was associated with higher BCM (Table 4, Figure 1). The model predicted 
an absolute probability of five-year BCM among ever-lymphopenic patients of 15%, compared 
to 4% for never-lymphopenic patients (95% CI: 12%-17% for ever-lymphopenic patients versus 
95% CI: 1%-6% for never-lymphopenic patients). 
 
We observed no interaction between carriage of deleterious BRCA1/2 mutations and minimum 
ALC in a complete case analysis (HR: 0.58, CI: 0.30-1.09, Supplemental Table 2). Given the 
high number of missing values (77% of patients untested for BRCA1/2, 48% without reported 
ALC), we conducted a multivariable Cox regression analyses using multiple imputation of 
BRCA1/2 values in the cohort that was used in the complete case analysis (n=759). Results were 
unchanged with multiple imputation (Supplemental Table 3).  
 
ALC, OM and BCM over Time 
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Higher ALC was associated with lower OM, with an ALC-time interaction of borderline 
statistical significance (p=0.06), implying that the magnitude of ALC/OM association may 
increase with time. A significant association was seen in the BCM model: at diagnosis, a 1 K/µL 
increase in ALC had an OR of 0.16 (95% CI: 0.08-0.32). One year post-diagnosis (Year 2), this 
OR was 0.14 (CI: 0.08-0.26). This significant inverse association of ALC and BCM continued 
monotonically through the sixth year post-diagnosis (OR 0.10, CI: 0.04-0.21; Table 5).  
Furthermore, temporal analyses for the radiotherapy and neutropenia variables were performed 
and showed that having radiotherapy after having a minimum ALC measurement (versus not 
having radiotherapy) was significantly associated with reduced mortality (HR: 0.02, 95% CI: 
0.05, 0.30), whereas radiotherapy before a minimum ALC value (vs. no radiotherapy) was not 
significantly associated with mortality. There was no evidence to suggest that the timing of 
neutropenia relative to the timing of the minimum ALC measurement had a protective effect 
(Supplemental Tables 4-7).  
 
Exploratory Analysis of TILs, ALC and Other Lymphocyte Counts 
For the 70 neoadjuvant chemotherapy trial participants with pre-treatment stromal TIL 
information, TILs had a borderline positive association with pre-treatment ALC (p=0.05, 
rho=0.25), but not pre-treatment percent peripheral lymphocytes (p=0.49, rho=0.08). By contrast, 
there was a statistically significant positive association between TILs and the minimum percent 
lymphocyte value collected at any time including during neoadjuvant chemotherapy (p=0.02, 
rho=0.28, Supplemental Figure 2; Supplemental Figure 3 shows a comparison between 
minimum absolute lymphocyte count and minimum lymphocyte percent). An exploratory 
analysis of pathologic complete response (pCR) to neoadjuvant chemotherapy in 60 of the 
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clinical trial patients with both TIL and response data available showed no significant association 
between minimum ALC value (p=0.62) or ever having lymphopenia (p=0.53) and achieving 
pCR to neoadjuvant chemotherapy (data not shown). 
 
Sensitivity Analysis 
Of 532 patients with percent lymphocyte counts available, higher percent lymphocyte counts 
were associated with lower BCM and OM (HR: 0.91, 95% CI: 0.88-0.95, and HR: 0.92, 95% CI: 
0.89-0.94, respectively; Supplemental Tables 8 and 9). Since more patients had ALC data 
available (n=747, compared to 532 with percent lymphocyte count data), we present the ALC 
analysis primarily. To investigate the possibility that metastatic recurrence (and subsequent 
chemotherapy) caused the observed association between higher lymphocyte counts and lower 
mortality, we restricted ALC values to the first year post-diagnosis, when metastatic recurrence 
is rare. We observed the same inverse association of minimum ALC with BCM and OM when 
we restricted ALC values to the first year post-diagnosis, which offers evidence that a low ALC 
due to treatment of metastatic recurrence does not explain the observed finding of higher BCM 
and OM. Furthermore, we defined the term ‘pre-chemotherapy’ ALC as an ALC value measured 
within three months of breast cancer diagnosis. We found the same inverse association of 
minimum ALC with OM but not with BCM with this restricted sample size (512 patients had a 
baseline measure of ALC within the first three months of diagnosis, and 29 patients [6%] met the 
criteria of lymphopenia [ALC  <1.0 K/µL]) (Supplemental Figures 4-6). In order to address the 
temporal relationship between laboratory measures and neoadjuvant/adjuvant chemotherapy 
receipt, we created indicator variables in our survival models for the time order of ALC and 
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chemotherapy. The time sequence variable was not significantly associated with BCM or OM 
(data not shown). 
 
Discussion 
We found that peripheral ALC post-diagnosis was a strong predictor of BCM and OM among a 
large cohort of patients with stages I-III TNBC. Notably, this inverse association between ALC 
and mortality appeared to strengthen over time: in the sixth year post-diagnosis, there was an 
absolute difference of >10% in BCM among ever-lymphopenic versus never-lymphopenic 
TNBC patients (15% and 4%, respectively). The increasing separation of mortality curves over 
time might be consistent with an immune effect that enhances response to initial therapy of 
TNBC. Moreover, in a cohort of TNBC patients treated on a prospective clinical trial with 
available TIL data, there was a direct correlation between higher TILs and higher peripheral 
lymphocyte counts during neoadjuvant chemotherapy. 
 
To our knowledge, this is the first study to demonstrate a significant inverse association between 
peripheral lymphocyte counts and cancer-specific mortality in patients with potentially curable 
TNBC. Among breast cancer subtypes, TNBC has the worst prognosis, yet also the strongest 
evidence for an effect of TILs on survival (9, 11, 12). Two recent studies showed that with every 
10% increase in stromal TILs there was an associated reduction in the risk of TNBC relapse or 
death (35). Taken together with recent TIL studies, the present results strengthen the case for 
ongoing trials of PD-1, PDL-1 and other immunotherapies in TNBC (16, 19). Furthermore, this 
study raises the question as to whether strategies to protect lymphocytes from chemotherapy in 
the adjuvant setting might be beneficial. On multivariable analysis, the main predictor of 
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developing lymphopenia was neoadjuvant/adjuvant chemotherapy use. Prospective studies 
should be conducted to characterize the development of and risk factors for lymphopenia, in 
addition to its association with the presence of  TILs and the tumor response to therapy. 
 
This study adds a piece to the intriguing puzzle of how the immune system mediates treatment 
response and cure in TNBC. Immuno-editing, the concept of tumor recognition by the host 
immune system, host protection against the tumor, and tumor escape (36-38), has garnered more 
recognition with recent advances in immunotherapy (14-17). It is increasingly evident that 
therapy-associated lymphocyte depletion in breast cancer patients can be associated with 
opportunistic infections, such as pneumocystis carinii pneumonia (39-41), similar to other 
immunocompromised hosts, such as those on long-term corticosteroid use or with acquired 
immunodeficiency syndrome (42-45).  One emerging theory is that tumors with greater 
mutational burden are more immunogenic and thus respond better to drugs that target the 
interplay between host and tumor immune responses (15, 46). Most TNBCs have basal-like 
subtype on gene expression profiling and high histologic grade, possibly denoting greater 
genomic instability in comparison to hormone receptor-positive breast cancers (13, 47). 
Furthermore, approximately 20% of TNBC patients have a deleterious germline BRCA1/2 
mutation, which is an inherited defect in DNA double-strand repair that causes tumor genomic 
instability (48, 49). One-quarter of tested patients in the present study carried a BRCA1/2 
mutation, but we did not observe a significant interaction between BRCA1/2 mutations and ALC 
on mortality. However, this null result might relate to low genetic testing rates in this 2000-2014 
diagnosis cohort: more than 70% were untested according to Myriad Genetics, the only 
laboratory that provided clinical BRCA1/2 testing during most of the study period. The low 
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testing rate reflects changes in understanding of the genetic causes of TNBC over time, since 
BRCA1/2 testing of all TNBC patients diagnosed at age <60 was not widely recommended until 
the later years of the study period . Moreover, recent work has shown that several other DNA 
repair gene mutations are associated with TNBC, and might cause a similar genomic instability 
phenotype as with BRCA1/2 (48). Future studies of TNBC patients tested for germline BRCA1/2 
and other DNA repair gene mutations, in addition to genomic instability assays such as the 
homologous recombination deficiency assay (29, 50), will be essential to answer questions about 
immune function and mortality in TNBC. 
 
Aspects of this study warrant consideration. Limitations include its retrospective design and 
restrictions inherent to using clinical information that was not originally collected for research 
purposes, notably missing data. In particular, we cannot rule out the possibility that patients with 
poorer prognosis more often had blood counts measured. However, it is reassuring that low ANC 
was not associated with higher mortality, suggesting that the observed results are lymphocyte-
specific. Furthermore, a sensitivity analysis restricted to ALC values measured within the first 
year post-diagnosis (a time period before most metastatic recurrences) showed consistent 
associations with OM and BCM. We addressed missing data using multiple imputation methods, 
which yielded similar results as complete-case analysis. The Oncoshare database focuses on a 
single geographic area with disproportionately high numbers of NH Whites and Asians, and thus 
may not fully represent all TNBC patients. Fortunately, providers across different healthcare 
settings used the same EMR: thus laboratory values and reference ranges were consistent across 
sites and did not constitute a source of bias. Random error may have contributed to the reported 
associations being underestimates of the true values. The intriguing temporal relationship 
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between radiotherapy and minimum ALC measurements warrant further study, specifically 
evaluating the duration of lymphopenia, which we were unable to do using our current data 
source. Furthermore, additional research elucidating the temporal relationship between 
chemotherapy, radiotherapy and lymphopenia is warranted to understand the range of 
determinants associated with these findings. As with any observational study, causality inferred 
from associations can be misleading due to uncontrolled selection bias or confounding. While 
provocative, the correlation we observed between TILs and lymphocyte counts during 
neoadjuvant therapy is derived from an exploratory analysis, and thus must be considered 
hypothesis-generating only.  
 
This study’s limitations are offset by its considerable strengths: the large number of TNBC 
patients (>1,400); long-term, highly complete mortality data available through SEER database 
linkage; detailed laboratory results available from EMRs and a genetic testing laboratory; and the 
real-world scope of more than one healthcare system, including an academic referral center and a 
community-based, multi-site practice. 
 
In summary, we report a substantial, specific and lasting inverse association between peripheral 
lymphocyte counts and cancer-specific and overall mortality among women with potentially 
curable TNBC. These results add to an emerging understanding of immune function in TNBC. In 
future clinical trials for TNBC, peripheral lymphocyte counts should be explored in connection 
with TILs as a potential biomarker for treatment efficacy and survival. 
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Figure Legend: 
 
Figure 1. Kaplan-Meier curves showing overall survival and breast cancer-specific survival as a 
function of absolute 
 lymphocyte count (ALC) (lymphopenia defined as ALC < 1 K/µL).  
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Table 1. Patient demographics for all patients and for the subset with a reported absolute lymphocyte count 
(ALC) at any time after breast cancer diagnosis  
All patients 
(N=1,463) 
Reported ALC 
(N=759) 
No reported ALC 
(N=704) 
Age in years 
  Mean (standard deviation, SD) 54 (± 14) 53 (± 14) 55 (± 14) 
Neighborhood socioeoconomic status, statewide quintiles (1=lowest, 5=highest) 
  Mean (SD) 4.0 (±1.2) 4.1 (±1.2) 3.8 (±1.2) 
Race/ethnicity 
  Non-Hispanic (NH) White 1,049 (72%) 543 (72%) 506 (72%) 
  NH Black 71 (5%) 36 (5%) 35 (5%) 
  NH Asian 203 (14%) 116 (15%) 87 (12%) 
  Hispanic 140 (9%) 64 (8%) 76 (11%) 
American Joint Committee on Cancer Stage 
I 514 (35%) 255 (34%) 259 (37%) 
II 714 (49%) 383 (50%) 331 (47%) 
III 235 (16%) 121 (16%) 114 (16%) 
Grade 
1 52 (4%) 24 (3%) 28 (4%) 
2 263 (18%) 134 (18%) 129 (18%) 
3 1,070 (73%) 566 (75%) 504 (72%) 
Unknown 78 (5%) 35 (5%) 43 (6%) 
Received neoadjuvant/adjuvant chemotherapy 
  Yes 1,113 (76%) 611 (81%) 502 (71%) 
  No 350 (24%) 148 (19%) 202 (29%) 
Received radiation therapy 
  Yes 675 (46%) 338 (45%) 337 (48%) 
  No 788 (54%) 421 (55%) 367 (52%) 
Germline BRCA1/2 mutation status
†
  Positive for a deleterious mutation in either gene 80 (5%) 56 (7%) 24 (3%) 
  Negative and/or variant of uncertain significance 258 (18%) 165 (22%) 93 (13%) 
  Untested 1,125 (77%) 538 (71%) 587 (83%) 
Ever neutropenic 
  Yes 142 (19%) 142 (19%) -- 
  No 618 (81%) 617 (81%) -- 
Baseline neutropenia 
 Yes 50 (10%) 50 (10%) -- 
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All patients 
(N=1,463) 
Reported ALC 
(N=759) 
No reported ALC 
(N=704) 
  No 462 (90%) 455 (90%) -- 
Minimum ALC (K/L) post-diagnosis††
Mean (SD) 0.9 (±0.6) 0.9 (±0.6) -- 
Ever lymphopenic 
 Yes 481 (63%) 481 (63%) -- 
 No 278 (37%) 278 (37%) -- 
Baseline lymphopenia 
 Yes 148 (29%) 147 (29%) -- 
 No 362 (71%) 357 (71%) -- 
†
 BRCA contains an additional ‘Untested’ category 
††
 Definition of lymphopenia: < 1K/L 
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Table 2. Multivariable analysis of predictors of lymphopenia (absolute lymphocyte count [ALC] <1K/L;  
n=747); statistically significant variables are in bold font. 
 
 
Odds ratio  
(95% confidence interval) 
Neighborhood socioeoconomic status (vs. 1=lowest) 1.06 (0.88, 1.28) 
Non-Hispanic (NH) Black (vs. NH White) 0.50 (0.14, 1.43) 
NH Asian (vs. NH White) 1.02 (0.58, 1.76) 
Hispanic (vs. NH White) 1.20 (0.52, 2.63) 
Positive for deleterious mutation in BRCA1/2
† 
(vs. negative/VUS
††
) 1.11 (0.50, 2.42) 
Age at diagnosis (per year) 0.99 (0.98, 1.01) 
Stage II (vs. Stage I) 0.72 (0.46, 1.12) 
Stage III (vs. Stage I) 1.84 (1.03, 3.28) 
Grade 2 (vs. Grade 1) 2.18 (0.55, 14.58) 
Grade 3 (vs. Grade 1) 3.64 (0.99, 23.52) 
Unknown grade (vs. Grade 1) 2.06 (0.37, 16.19) 
†
 BRCA1/2 contains an additional ‘Untested’ category. 
†† 
VUS: Variant of uncertain significance. 
††† 
ANC: absolute neutrophil count. 
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Table 3. Multivariable analysis of the association between minimum absolute lymphocyte count (ALC) and 
overall mortality (n=747); statistically significant variables are in bold font. 
 
Hazard ratio 
(95% confidence interval) 
Minimum ALC 0.23 (0.16, 0.35) 
Neoadjuvant/adjuvant chemotherapy use (versus [vs.] none) 0.53 (0.34, 0.84) 
Radiotherapy use (vs. none) 0.75 (0.54, 1.03) 
Neighborhood socioeoconomic status (vs. 1=lowest) 0.85 (0.74, 0.97) 
Non-Hispanic (NH) Black (vs. NH White) 1.72 (0.91, 3.24) 
NH Asian (vs. NH White) 0.98 (0.62, 1.54) 
Hispanic (vs. NH White) 1.29 (0.75, 2.23) 
Positive for deleterious mutation in BRCA1/2
† 
(vs. negative/VUS
†
) 0.87 (0.40, 1.91)  
Untested for deleterious mutation in BRCA1/2
† 
(vs. negative/VUS
†
) 1.45 (0.91, 2.32) 
Age at diagnosis (per year) 1.01 (1.00, 1.03) 
Ever neutropenic (ANC < 1 K/L) †† (vs. never neutropenic) 1.06 (0.72, 1.55) 
Stage II (vs. Stage I) 1.47 (0.97, 2.23) 
Stage III (vs. Stage I) 4.25 (2.69, 6.74) 
Grade 2 (vs. Grade 1) 2.58 (0.60,11.05) 
Grade 3 (vs. Grade 1) 3.82 (0.93,15.72) 
Unknown grade (vs. Grade 1) 2.18 (0.46,10.35) 
† 
VUS: Variant of uncertain significance. 
††
ANC: absolute neutrophil count. 
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 Table 4. Multivariable analysis of the association between minimum absolute lymphocyte count (ALC) 
and breast cancer-specific mortality (n=747); statistically significant variables are in bold font. 
 
                Hazard ratio 
(95% confidence interval) 
Minimum ALC 0.19 (0.11, 0.34) 
Neoadjuvant/adjuvant chemotherapy use (versus [vs.] none) 0.54 (0.29, 1.01) 
Radiotherapy use (vs. none) 0.70 (0.46, 1.06) 
Neighborhood socioeoconomic status (vs. 1=lowest) 0.85 (0.71, 1.00) 
Non-Hispanic (NH) Black (vs. NH White) 1.54 (0.66, 3.55) 
NH Asian (vs. NH White) 0.78 (0.42, 1.44) 
Hispanic (vs. NH White) 1.35 (0.71, 2.56) 
Positive for deleterious mutation in BRCA1/2
†  
(vs. negative/VUS
††
) 0.98 (0.36, 2.64) 
Untested for deleterious mutation in BRCA1/2
†  
(vs. negative/VUS
††
) 1.91 (1.01, 3.59) 
Age at diagnosis (per year) 0.99 (0.98, 1.01) 
Ever neutropenic (ANC < 1 K/L) †††  (vs. never neutropenic) 1.01 (0.63, 1.62) 
Stage II (vs. Stage I) 2.61 (1.37, 4.97) 
Stage III (vs. Stage I) 7.59 (3.83,15.04) 
Grade 2 (vs. Grade 1) 2.27 (0.29,17.66) 
Grade 3 (vs. Grade 1) 3.06 (0.41,22.69) 
Unknown grade (vs. Grade 1) 1.08 (0.11,10.65) 
†
 BRCA1/2 contains an additional ‘Untested’ category. 
†† 
VUS: Variant of uncertain significance. 
††† 
ANC: absolute neutrophil count. 
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Table 5. Unadjusted association between absolute lymphocyte count (ALC), time in years since breast cancer 
diagnosis, and overall and breast cancer-specific mortality 
Overall mortality 
(n=747) 
Breast cancer-specific 
mortality (n=747) 
ALC over time 
Odds ratio 
(95% confidence interval) 
Odds ratio  
 (95% confidence interval) 
Diagnosis-12 months (Year 1) 0.34 (0.23,0.49) 0.16 (0.08,0.32) 
12-24 months (Year 2) 0.30 (0.22,0.42) 0.14 (0.08,0.26) 
25-36 months (Year 3) 0.27 (0.20,0.37) 0.13 (0.07,0.22) 
37-48 months (Year 4) 0.24 (0.18,0.33) 0.12 (0.07,0.21) 
49-60 months (Year 5) 0.21 (0.15,0.31) 0.11 (0.05,0.20) 
61-72 months(Year 6) 0.19 (0.13,0.29) 0.10 (0.04,0.21) 
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Figure 1. 
Note: Drop in never-lymphopenic overall survival is due to death of the patient with the longest follow up time. The shaded areas 
represent the confidence intervals for each curve. 
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